<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sensorion Sas — News on 6ix</title>
<link>https://6ix.com/company/sensorion-sas</link>
<description>Latest news and press releases for Sensorion Sas on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 05:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sensorion-sas" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52c8dbeedb30cb6f6baa9.webp</url>
<title>Sensorion Sas</title>
<link>https://6ix.com/company/sensorion-sas</link>
</image>
<item>
<title>Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 11, 2026</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-provides-preliminary-documents-for-the-combined-shareholders-general-meeting-of-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-provides-preliminary-documents-for-the-combined-shareholders-general-meeting-of-may-11-2026</guid>
<pubDate>Tue, 21 Apr 2026 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, April 21, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Monday 11 May 2026, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris (France).</description>
</item>
<item>
<title>Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-in-Human Clinical Development</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-reports-six-month-update-from-the-audiogene-phase-12-trial-of-sens-501-and-advances-gjb2-gt-sens-601-toward-first-in-human-clinical-development</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-reports-six-month-update-from-the-audiogene-phase-12-trial-of-sens-501-and-advances-gjb2-gt-sens-601-toward-first-in-human-clinical-development</guid>
<pubDate>Mon, 23 Mar 2026 06:30:00 GMT</pubDate>
<description>MONTPELLIER, France, March 23, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported updated six-month efficacy data from Cohort 2 of the Audiogene Phase 1/2 clinical trial evaluating SENS-501, its gene therapy for the treatment of otoferlin-mediated congenital deafness, and provided a timeline update on the advancement of its</description>
</item>
<item>
<title>Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-reports-full-year-2025-results-provides-corporate-update-and-announces-release-of-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-reports-full-year-2025-results-provides-corporate-update-and-announces-release-of-annual-report</guid>
<pubDate>Wed, 18 Mar 2026 06:30:00 GMT</pubDate>
<description>MONTPELLIER, France, March 18, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corporate update, and announced the availability of the annual report.</description>
</item>
<item>
<title>Sensorion Announces Leadership Changes</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-leadership-changes</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-leadership-changes</guid>
<pubDate>Tue, 17 Feb 2026 06:30:00 GMT</pubDate>
<description>MONTPELLIER, France, February 17, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, Sensorion’s Chief Executive Officer and a Director on the Company’s Board, is stepping down from both posts due to a personal matter incompatible with serving as Chief Executive Officer. Amit Munshi, who serves as the Ch</description>
</item>
<item>
<title>Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-the-association-for-research-in-otolaryngology-aro-49th-annual-midwinter-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-the-association-for-research-in-otolaryngology-aro-49th-annual-midwinter-meeting</guid>
<pubDate>Fri, 06 Feb 2026 06:30:00 GMT</pubDate>
<description>MONTPELLIER, France, February 06, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting, taking place on February 7-11, 2026, in San Juan, Puerto Rico.</description>
</item>
<item>
<title>Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-euro60-million-financing-with-a-euro20m-strategic-investment-from-sanofi-and-support-from-global-healthcare-specialists-to-advance-genetic-medicine-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-euro60-million-financing-with-a-euro20m-strategic-investment-from-sanofi-and-support-from-global-healthcare-specialists-to-advance-genetic-medicine-pipeline</guid>
<pubDate>Wed, 28 Jan 2026 06:43:00 GMT</pubDate>
<description>MONTPELLIER, France, January 28, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced a €60 million offering reserved to specific categories of investors (the "Reserved Offering") through the issuance of 214,285,714 new ordinary shares of the Company (the "New Shares") at a price per New Share of €0.28 (the "Subscriptio</description>
</item>
<item>
<title>Sensorion to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Fri, 19 Dec 2025 06:30:00 GMT</pubDate>
<description>MONTPELLIER, France, December 19, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced today that it will participate in the 44th Annual J.P. Morgan Healthcare Conference, San Francisco, USA, to be held on January 12-15, 2026.</description>
</item>
<item>
<title>Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-reports-independent-data-monitoring-committee-raises-no-safety-concerns-and-agrees-to-continue-sens-501s-audiogene-phase-12-trial</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-reports-independent-data-monitoring-committee-raises-no-safety-concerns-and-agrees-to-continue-sens-501s-audiogene-phase-12-trial</guid>
<pubDate>Mon, 08 Dec 2025 06:30:00 GMT</pubDate>
<description>MONTPELLIER, France, December 08, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Data Monitoring Committee (DMC) supports the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, the Company’s gene therapy program being developed to treat a specific form of congenital deafness linked to mutation</description>
</item>
<item>
<title>Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-reports-2025-half-year-results-provides-corporate-update-and-announces-availability-of-half-year-report</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-reports-2025-half-year-results-provides-corporate-update-and-announces-availability-of-half-year-report</guid>
<pubDate>Wed, 17 Sep 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, September 17, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its half-year 2025 results, provided a corporate update and announced the availability of the half-year report.</description>
</item>
<item>
<title>Sensorion Announces its Participation in the 60th Annual Inner Ear Biology Workshop</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-the-60th-annual-inner-ear-biology-workshop</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-the-60th-annual-inner-ear-biology-workshop</guid>
<pubDate>Thu, 04 Sep 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, September 04, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation in the 60th annual Workshop on Inner Ear Biology, held on September 13-16, 2025, Tübingen, Germany.</description>
</item>
<item>
<title>Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux</guid>
<pubDate>Fri, 15 Aug 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, August 15, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux.</description>
</item>
<item>
<title>Sensorion Announces Its Participation In Upcoming Investor Conferences</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-upcoming-investor-conferences</guid>
<pubDate>Thu, 31 Jul 2025 07:17:00 GMT</pubDate>
<description>MONTPELLIER, France, July 31, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced its participation in upcoming investor conferences to be held in September and October 2025.</description>
</item>
<item>
<title>Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-completes-patient-enrollment-of-the-second-cohort-in-audiogene-phase-12-gene-therapy-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-completes-patient-enrollment-of-the-second-cohort-in-audiogene-phase-12-gene-therapy-clinical-trial</guid>
<pubDate>Tue, 29 Jul 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, July 29, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the completion of patient enrollment in the second cohort of its Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations</description>
</item>
<item>
<title>Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-preliminary-positive-data-from-the-first-cohort-of-the-audiogene-phase-12-gene-therapy-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-preliminary-positive-data-from-the-first-cohort-of-the-audiogene-phase-12-gene-therapy-clinical-trial</guid>
<pubDate>Tue, 01 Jul 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, July 01, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced preliminary positive data from the first cohort of the Phase 1/2 Audiogene clinical trial evaluating the low dose of SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutat</description>
</item>
<item>
<title>Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-publishes-results-of-combined-shareholders-general-meeting-resolutions</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-publishes-results-of-combined-shareholders-general-meeting-resolutions</guid>
<pubDate>Tue, 13 May 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, May 13, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the results of resolutions presented at its Combined General Meeting (CGM), held on May 12, 2025, and made them available on the dedicated section of its website.</description>
</item>
<item>
<title>Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-the-american-society-of-cell-and-gene-therapy-asgct-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-its-participation-in-the-american-society-of-cell-and-gene-therapy-asgct-annual-meeting</guid>
<pubDate>Tue, 06 May 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, May 06, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced its participation at the 28th Annual American Society of Cell and Gene Therapy Meeting (ASGCT), taking place on May 13-17, 2025, in New-Orleans, United States of America.</description>
</item>
<item>
<title>Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting</title>
<link>https://6ix.com/company/sensorion-sas/news/sensorion-announces-presentation-by-pr-natalie-loundon-at-the-2025-american-society-of-pediatric-otolaryngology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/sensorion-sas/news/sensorion-announces-presentation-by-pr-natalie-loundon-at-the-2025-american-society-of-pediatric-otolaryngology-annual-meeting</guid>
<pubDate>Fri, 25 Apr 2025 05:30:00 GMT</pubDate>
<description>MONTPELLIER, France, April 25, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Pr. Natalie Loundon, pediatric ENT Surgeon, Director of the Center for Research in Pediatric Audiology, Necker Enfants Malades Hospital, AP-HP, in Paris, France, will make an oral presentation at the annual meeting of the American Societ</description>
</item>
</channel>
</rss>